Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the more suitable treatment for the prevention of vascular complications in diabetes patents who were at high cardiovascular risk group by comparing the platelet aggregation inhibitory effect of aspirin and cilostazol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kangbuk Samsung Hospital
• Collaborator: Asan Medical Center
• Treatments: Aspirin; Cilostazol

Criteria

Inclusion Criteria:

• Who have one more following risk factor:

• Family history of cardiovascular disease

• Hypertension

• Smoking History

• Dyslipidemia

• Albuminuria

• Who do not have high risk of bleeding

• Who stop taking Cilostazol or Aspirin before randomized period 1months or

• Who have never taken the drugs

Exclusion Criteria:

• Type 1 diabetes mellitus, gestational diabetes

• Who with history of macrovascular complication including cardiovascular disease, cerebrovascular disease and peripheral vascular disease